Weekly GLP-1 medicine for blood sugar issues in adults with CF
Treatments studied
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Lungs & breathing clinical trials.
This Phase 2 trial tests a weekly GLP-1 medicine (dulaglutide) to improve blood sugar control in adults with cystic fibrosis (CF) who have trouble managing glucose. It may help people with CF-related prediabetes or diabetes by improving how their body handles sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can take medicine by injection under the skin once a week.
- You have confirmed cystic fibrosis (usually from a positive sweat test or CF gene testing).
- You need pancreatic enzyme replacement for pancreatic insufficiency.
- You have abnormal blood sugar results on an oral glucose test (OGTT) or have CF-related diabetes (CFRD).
- Your body weight is not too low (BMI must be at least 19).
- If you can become pregnant, you must use very effective birth control during the study and for 6 weeks after the last dose (condoms alone don’t count).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
This study tests a drug called dorzagliatin to see if it can help control blood sugar in adults with cystic fibrosis who have pancreatic insufficiency and abnormal glucose tolerance.
This trial studies whether a low glycemic load (a specific way of choosing carbohydrates) improves blood sugar control and body composition in adults with cystic fibrosis–related diabetes. It may help reduce blood sugar problems and support healthier weight and body measurements.
This trial tests if a weekly injection of dulaglutide (Trulicity) can help children with type 2 diabetes control their blood sugar when used together with metformin and/or insulin. It may be an option for kids who are overweight.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial tests whether a GLP-1 receptor agonist can help improve irregular periods in teenage girls with type 1 diabetes. It's for girls aged 12 to 18 who have had their period for at least 2 years, use a continuous glucose monitor, and have higher blood sugar levels (HbA1c of 7% or more).
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.